Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
16 Outubro 2023 - 9:03AM
Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”)
(Nasdaq: CPRX), a commercial-stage biopharmaceutical company, today
announced that Patrick J. McEnany, Founder, Chairman and CEO of
Catalyst, has been bestowed the 2023 Lifetime Achievement Award by
BioFlorida at their Annual Meeting last Friday. This prestigious
award highlights Mr. McEnany's outstanding accomplishments,
unwavering commitment to rare disease patients, dedication to
Catalyst’s employees, and pivotal role in fostering the growth of
Florida's biopharmaceutical ecosystem.
"I extend my heartfelt gratitude to BioFlorida
for bestowing this distinguished honor and recognition upon me.
Guiding Catalyst's transformation from a modest startup into a
thriving enterprise has been a source of immense fulfillment,”
stated Mr. McEnany, Founder, Chairman, and CEO of Catalyst. “Our
unwavering commitment to the rare-disease patient community that we
serve has been the driving force behind our Company's success,
fueled by the collective contributions of all of our Catalyst team
members. I am profoundly thankful to all who have been a part of my
remarkable journey."
"It is our pleasure to celebrate Patrick
McEnany’s illustrious career and contribution to Florida’s economic
development through BioFlorida’s 2023 Lifetime Achievement Award,”
said Nancy K. Bryan, President and CEO of BioFlorida. “Through his
work and accomplishments, Mr. McEnany has profoundly impacted not
only his immediate local community in Coral Gables but also the
broader state of Florida. We are thrilled to recognize his
remarkable contributions to the field of rare diseases, symbolizing
his unwavering dedication to improving the lives of those facing
these challenging medical conditions.”
This award recognizes Mr. McEnany's visionary
leadership and significant contributions as a distinguished
co-founder, Chairman, President, and Chief Executive Officer of
Catalyst. Since the Company’s inception in January 2002, Mr.
McEnany has been at the helm, serving as CEO and a dedicated member
of the Company’s board of directors. His pivotal roles as Chairman
and President were assumed in March 2006, marking an important
milestone in his leadership journey.
Prior to founding Catalyst, Mr. McEnany was
previously the Chairman and CEO at Royce Laboratories, Inc., a
Miami-based generic pharmaceutical manufacturer, from 1991 to 1997.
Following the merger of Royce Laboratories into Watson
Pharmaceuticals, Inc., Mr. McEnany continued to play an
instrumental role, serving as the President of the wholly owned
Royce Laboratories subsidiary of Watson, as well as Vice President
of Corporate Development for Watson until 1999. During his tenure,
he also assumed the role of Vice Chairman and Director at the
National Association of Pharmaceutical Manufacturers from 1993 to
1997.
Mr. McEnany's unwavering commitment to the
community is reflected in his active involvement in philanthropic
initiatives. He currently serves on the emeritus board of directors
of the Jackson Health Foundation and the board of directors of the
Humane Society of Greater Miami. Over the last three decades, he
has provided his expertise as a director to numerous public
companies, contributing his extensive knowledge and leadership
acumen to their growth and success.
About Catalyst
PharmaceuticalsWith exceptional patient focus, Catalyst is
committed to developing and commercializing innovative
first-in-class medicines that address rare neurological and
epileptic diseases. Catalyst's flagship U.S. commercial
product is FIRDAPSE® (amifampridine) Tablets 10 mg, approved
for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS") for
adults and for children ages six to seventeen. In January
2023, Catalyst acquired the U.S. commercial rights to
FYCOMPA® (perampanel) CIII, a prescription medicine approved
in people with epilepsy aged four and older alone or with other
medicines to treat partial-onset seizures with or without
secondarily generalized seizures and with other medicines to treat
primary generalized tonic-clonic seizures for people with epilepsy
aged 12 and older. Further, Canada's national healthcare
regulatory agency, Health Canada, has approved the use of
FIRDAPSE for the treatment of adult patients
in Canada with LEMS. Finally, on July 18, 2023,
Catalyst acquired an exclusive license for North
America for vamorolone, a promising best-in-class dissociative
anti-inflammatory steroid treatment for Duchenne Muscular
Dystrophy. Vamorolone has received FDA Orphan Drug and Fast
Track designations and has been granted a PDUFA action date
of October 26, 2023.
For more information about Catalyst
Pharmaceuticals, Inc., visit the Company's website
at www.catalystpharma.com. For Full Prescribing and Safety
Information for FIRDAPSE®, visit www.firdapse.com. For Full
Prescribing Information, including Boxed WARNING for FYCOMPA®,
please visit www.fycompa.com.
Forward-Looking StatementsThis
press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which
may cause Catalyst's actual results in future periods to differ
materially from forecasted results. A number of factors, including
those factors described in Catalyst's Annual Report on Form 10-K
for the fiscal year 2022 and its other filings with the U.S.
Securities and Exchange Commission ("SEC"), could adversely
affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on
Catalyst's website, or may be obtained upon request from Catalyst.
Catalyst does not undertake any obligation to update the
information contained herein, which speaks only as of this
date.
Source: Catalyst Pharmaceuticals, Inc.
Contacts:
Investor Relations:
Mary Coleman
Catalyst Pharmaceuticals
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact:
David Schull
Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024